Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biomarin Pharmaceutical Inc BMRN

Healthcare Biotechnology
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec... see more

Recent & Breaking News (NDAQ:BMRN)

Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. (BMRN) Investors of Class Action

Business Wire December 22, 2021

BMRN Final Deadline Today: Rosen, a Longstanding Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action - BMRN

Newsfile December 22, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN

PR Newswire December 21, 2021

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in BioMarin Pharmaceutical Inc. with Losses of $100,000 to Contact the Firm

PR Newswire December 21, 2021

BMRN FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important Wednesday Deadline in Securities Class Action - BMRN

Newsfile December 20, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN

Newsfile December 16, 2021

BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases

PR Newswire December 16, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN

PR Newswire December 15, 2021

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

PR Newswire December 15, 2021

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 22 Deadline in Securities Class Action - BMRN

PR Newswire December 14, 2021

BioMarin Update

Newsfile December 12, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN

Newsfile December 11, 2021

BioMarin Class Action Reminder

Newsfile December 10, 2021

BioMarin Shareholder Notice

Newsfile December 9, 2021

BMRN Investor Notice: Rosen, a Global and Leading Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 22 Deadline in Securities Class Action - BMRN

Newsfile December 9, 2021

BioMarin Shareholder Alert

Newsfile December 8, 2021

UPCOMING DEADLINE: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile December 7, 2021

BioMarin Deadline Alert

Newsfile December 7, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN

PR Newswire December 6, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN

Newsfile December 5, 2021